Literature DB >> 33977093

Reply to the Letter "Comment on Regarding Manuscript 'Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies'".

Kazuhiro Nouso1, Kazuya Kariyama1.   

Abstract

Entities:  

Year:  2021        PMID: 33977093      PMCID: PMC8077652          DOI: 10.1159/000514226

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  3 in total

1.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

Authors:  Norihiro Kokudo; Nobuyuki Takemura; Kiyoshi Hasegawa; Tadatoshi Takayama; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Namiki Izumi; Shuichi Kaneko; Masatoshi Kudo; Hiroko Iijima; Takuya Genda; Ryosuke Tateishi; Takuji Torimura; Hiroshi Igaki; Satoshi Kobayashi; Hideyuki Sakurai; Takamichi Murakami; Takeyuki Watadani; Yutaka Matsuyama
Journal:  Hepatol Res       Date:  2019-09-06       Impact factor: 4.288

2.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
Journal:  Gut       Date:  2019-12-04       Impact factor: 23.059

Review 3.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.

Authors:  Josep M Llovet; Augusto Villanueva; Jorge A Marrero; Myron Schwartz; Tim Meyer; Peter R Galle; Riccardo Lencioni; Tim F Greten; Masatoshi Kudo; Sumithra J Mandrekar; Andrew X Zhu; Richard S Finn; Lewis R Roberts
Journal:  Hepatology       Date:  2020-09-09       Impact factor: 17.425

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.